Enrico Gallitto, Gianluca Faggioli, Francesco Saia, Tullio Palmerini, Rodolfo Pini, Antonio Giulio Bruno, Francesca Maria Feroldi, Moad Alaidros, Gabriele Ghetti, Nevio Taglieri, Stefania Caputo, Francesco Donati, Cinzia Marrozzini, Mauro Gargiulo
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become the standard treatment for severe aortic valve stenosis in patients at increased surgical risk. Percutaneous transfemoral (TF) is the access of choice due to its reduced invasiveness and perioperative morbidity/mortality compared with the trans-axillary, aortic, and apical routes. On the other hand, vascular access complications (VACs) of the TF access are associated with prolonged hospitalization, 30-day, and 1-year mortality...
March 19, 2024: Vascular